香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 LUYE PHARMA GROUP LTD. 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 截 至2025年12月31日止年度之年度業績公告 財務摘要 – 1 – • 收入較截至2024年12月31日止年度增加人民幣247.0百萬元或4.1%至人民 幣6,308.4百 萬 元。 • EBITDA較截至2024年12月31日止年度增加人民幣279.0百萬元或12.7%至 人民幣2,470.7百 萬 元。 • 毛利較截至2024年12月31日止年度增加人民幣118.4百萬元或2.9%至人民 幣4,162.6百 萬 元，毛 利 率 達66.0%。 • 除稅前溢利較截至2024年12月31日止年度增加人民幣105.4百萬元或12.6% 至人民幣944.6百 萬 元。 • 溢利淨值為人民幣705 ...

LUYE PHARMA GROUP LTD. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 之全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何 責 任。 承董事會命 綠葉製藥集團有限公司 主 席 劉殿波 香 港，二 零 二 六 年 三 月 十 七 日 綠葉製藥集團有限公司 （於 百 慕 達 註 冊 成 立 之 有 限 公 司） （股 份 代 號：02186） 董事會會議通告 於 本 公 告 日 期，本 公 司 執 行 董 事 為 劉 殿 波 先 生、楊 榮 兵 先 生、袁 會 先 先 生 及 祝 媛 媛 女 士；本 公 司 非 執 行 董 事 為 宋 瑞 霖 先 生 及 黃 立 明 先 生；及 本 公 司 獨 立 非執行董事為張化橋先生、盧毓琳教授、梁民傑先生、蔡思聰先生及夏蓮女士。 綠葉製藥集團 有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司 將 於 二 零二六年三月三十日（星 期 一）舉 行 董 事 會 會 議，藉 以（其 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 绿叶制药集团有限公司 呈交日期: 2026年3月5日 第 2 頁 共 10 頁 v 1.2.0 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02186 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | | USD | | 0.02 USD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.02 USD | | 200 ...

Core Viewpoint - The A-share market has experienced increased volatility and divergence since the beginning of 2026, leading public funds to rapidly shift their investment logic towards undervalued, high-dividend, and highly certain stocks [1] Group 1: Market Trends - The ongoing discount recovery of AH shares, which are listed in both mainland China and Hong Kong, has been a significant trend, with public funds focusing on high-discount targets [1] - The pricing advantage of Hong Kong stocks has become more pronounced, with expectations of discount convergence driving valuation recovery for related companies [1] Group 2: Investment Strategies - The strategy of seeking safe havens has emerged as a key method for fund managers to achieve excess returns on individual stocks [1] - Companies such as Yituo Co., Zhejiang Shibao, and Andeli have become focal points for public funds' investments in the southbound market, with their Hong Kong-listed shares significantly outperforming their A-share counterparts this year [1]

Core Viewpoint - The financial maneuvers of Green Leaf Pharmaceutical, including the acquisition of a 25% stake in its subsidiary Nanjing Green Leaf and the introduction of high-interest financing, have drawn significant market attention due to their complexity and potential implications for the company's financial health [3][4][5]. Group 1: Acquisition and Financing Structure - Green Leaf Pharmaceutical announced the completion of a 25% stake buyback in Nanjing Green Leaf for approximately 1.086 billion yuan, with the stake now held by Nanjing Xinshi, a partnership involving Shandong Green Leaf and China Cinda Asset Management [3][6]. - The financing structure includes an 8.5% annual return for China Cinda, with a clear exit mechanism established through put options tied to Nanjing Green Leaf's future profitability and IPO plans [4][9]. - Nanjing Green Leaf is projected to achieve pre-tax net profits of 4.06 billion yuan in 2023 and 4.1 billion yuan in 2024, making it a core asset for Green Leaf Pharmaceutical [6][10]. Group 2: Financial Performance and Market Position - As of June 30, 2025, Green Leaf Pharmaceutical's capital debt ratio rose to 59.1%, primarily due to increased borrowings, with short-term loans reaching 7.668 billion yuan [8][9]. - Nanjing Green Leaf's main product, Lipusu, has faced pricing pressures and competition, impacting the company's revenue growth, which saw a decline of 1.3% year-on-year in 2024 [10][11]. - The company has 31 products in various stages of development in China, including 13 oncology products, and anticipates revenue growth driven by new product approvals and sales [11].

致：香港交易及結算所有限公司 公司名稱: 绿叶制药集团有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02186 | 說明 普通股 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 10,000,000,000 | | USD | | 0.02 | USD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.02 | USD | | 200,000,000 ...

Group 1 - The core announcement is that Green Leaf Pharmaceutical has entered into a capital injection agreement with several entities, which will result in a total investment of RMB 285 million [1] - Following the completion of the capital injection, the ownership structure of Nanjing Green Leaf will be as follows: Shenzhen Green Leaf will hold 70.01%, Nanjing Xinshi 23.34%, Nanjing Xinan 4.32%, and Ningbo Xinda 2.33% [1]

Core Viewpoint - The recent stock transfer of Green Leaf Pharmaceutical (02186) indicates a strategic shift in shareholder structure, with significant capital injection planned to strengthen its financial position [1] Group 1: Shareholder Changes - On January 26, a stock transfer occurred from Jianyin International Securities to UBS Securities Hong Kong Limited, with a market value of HKD 454 million, representing 3.88% of the total shares [1] - Following the stock transfer, the ownership structure of Nanjing Green Leaf will be as follows: Shenzhen Green Leaf will hold 70.01%, Nanjing Xinshi 23.34%, Nanjing Xinan 4.32%, and Ningbo Xinda 2.33% [1] Group 2: Capital Injection Agreement - On January 26, an investment agreement was established among Shenzhen Green Leaf, Nanjing Xinshi, Nanjing Xinan, Ningbo Xinda, and Nanjing Green Leaf, where Nanjing Xinan and Ningbo Xinda agreed to provide additional capital totaling RMB 285 million [1] - This capital injection is expected to enhance the operational capabilities and financial stability of Nanjing Green Leaf [1]

Group 1 - The core point of the article highlights the transfer of shares of Green Leaf Pharmaceutical (02186) from Jianyin International Securities to UBS Securities Hong Kong Limited, with a market value of HKD 454 million, representing 3.88% of the total shares [1] - Green Leaf Pharmaceutical announced a capital injection agreement on January 26, 2026, involving Shenzhen Green Leaf, Nanjing Xinshi, Nanjing Xinan, Ningbo Xinda, and Nanjing Green Leaf, with a total capital of RMB 285 million [1] - Following the completion of the capital injection, the ownership structure of Nanjing Green Leaf will be as follows: Shenzhen Green Leaf 70.01%, Nanjing Xinshi 23.34%, Nanjing Xinan 4.32%, and Ningbo Xinda 2.33% [1]

Core Viewpoint - Green Leaf Pharmaceutical (02186) announced a capital injection agreement involving multiple parties, which will enhance its financial position and ownership structure in its subsidiary, Nanjing Green Leaf [1] Group 1: Capital Injection Details - On January 26, 2026, Shenzhen Green Leaf, Nanjing Xinshi, Nanjing Xinan, Ningbo Xinda, and Nanjing Green Leaf entered into a capital injection agreement, totaling RMB 285 million [1] - Following the completion of the capital injection, the ownership of Nanjing Green Leaf will be held by Shenzhen Green Leaf (70.01%), Nanjing Xinshi (23.34%), Nanjing Xinan (4.32%), and Ningbo Xinda (2.33%) [1] Group 2: Rights and Agreements - A series of further transactions have been established regarding the capital injection, including an equity option agreement that allows Yantai Green Leaf to require the investors to sell their respective stakes in Nanjing Green Leaf [1] - The equity option agreement also grants the investors the right to request Yantai Green Leaf to repurchase their stakes under certain conditions [1] Group 3: Company Focus - Nanjing Green Leaf and its subsidiaries primarily engage in the production and sales of pharmaceuticals, with a focus on cancer treatment [1] - Yantai Green Leaf and Shenzhen Green Leaf are wholly-owned subsidiaries of the company, primarily involved in investment holding activities [1]